This demonstrates that the pharmacodynamic (PD) effects of FH outlast the presence of the molecule in the circulation, raising questions about the duration of FH efficacy following a single injection, and the potential of repeated CPV-104 administration to prevent recurring glomerular deposits. This evidence concerns the gene FH and familial hyperaldosteronism.